New drug aims to stop second strokes in High-Risk patients
NCT ID NCT07341958
Summary
This study tests whether adding a new cholesterol-lowering drug called Tolecilimab to standard treatment helps prevent second strokes in people who recently had a stroke or mini-stroke. Researchers will enroll 242 patients in China who have high levels of a specific cholesterol marker. Participants will receive either the new drug or a placebo along with their regular medication for 90 days to see if it reduces stroke recurrence risk.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE OR HIGH-RISK TIA (ABCD² ≥ 4) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hopital, Capital Medical University
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.